Border Zone Key in Vagal Nerve Stimulation

Article

Electrically stabilizing the myocardial border zone with vagal nerve stimulation (VNS) may offer a new mechanism for reducing arrhythmia.

Electrically stabilizing the myocardial border zone with vagal nerve stimulation (VNS) may offer a new mechanism for reducing arrhythmia. A University of California Los Angeles team is due to report Sunday, March 15 at the 2015 annual meeting of the American College of Cardiology in San Diego, CA.

Marmar Vaseghi, MD, a cardiologist at Ronald Reagan Medical Center, reported on an assessment of the regional electrophysiological effects of vagal nerve stimulation, bilateral stellate ganglia stimulation (SGS), and neurotransmitter content after myocardial infarction.

She looked at 15 infarcted and 7 normal pig hearts. VNS and SGS were performed and the inducibility of ventral tachycardia (VT) was assessed. The team then looked at activation recovery interval (ARI) recordings from both scarred and viable areas.

The researchers also analyzed acetylcholine (Ach) and norepinephrine content.

The results showed that VNS prolonged global ARI of infarcted more thannormal hearts. ACH content was greatin the border zone and viable regions of the infarcted hearts. VNS prolonged border zone ARI more than scar or viable areas and reduced border zone dispersion of repolarization significantly compared to other regions.

SGS shortened scar ARI as well as that in the border zone and viable myocardium and increased dispersion in all regions. VNS decreased VT inducibility from 60% to 30%.

“The greater response of VNS and Ach content of viable and border zone myocardium in infarcted hearts suggests a decrease in parasympathetic drive,” the researchers concluded, indicating that electrical stabilization of the border zone “is a novel mechanism for arrhythmia reduction with VNS.”

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.